Technology area: Biotechnology & Pharmaceuticals
18 pending office actions • 10 art units • 16 examiners • 0 of 18 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
St. Jude Children's Research Hospital Inc. has 18 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 16 distinct examiners and 10 distinct art units, showing substantial distribution across both personnel and technical groups. The portfolio therefore calls for structured monitoring rather than a single examiner-centered approach.
WANG, RUIXUE is the busiest examiner, with 2 pending matters. That figure represents a limited portion of the overall docket, so counsel should treat the matters as one examiner-specific subset within a broader biotechnology and pharmaceutical prosecution program. Grouping by art unit can help identify shared examination themes while preserving separate response plans for each examiner.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 5 (28%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 2 (11%) |
| Multi-statute (no §101) | 8 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, RUIXUE | 2 | 55.9% | +19.0% |
| GRABER, JAMES J | 2 | 46.5% | +57.6% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
| MERTZ, PREMA MARIA | 1 | 71.8% | +34.6% |
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
| WHITEMAN, BRIAN A | 1 | 68.4% | +16.8% |
| O'NEILL, MARISOL ANN | 1 | 54.5% | +68.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | LANDSMAN, ROBERT S | 24d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917198 | B7-H3 CHIMERIC ANTIGEN RECEPTORS | RIGA, MICHAEL ANGELO | 72d overdue |
| 18041873 | Use of Amylase or Maltose to Treat or Prevent Neurodegeneration | O'NEILL, MARISOL ANN | 9d |
| 16467358 | DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY | MOSS, NATALIE M | 70d |
| 18681966 | METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION | WANG, RUIXUE | — |
| 18565700 | INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER | MERTZ, PREMA MARIA | — |
| 18564987 | METHODS AND COMPOSITIONS FOR TRANSDUCTION OF NK CELLS | WANG, RUIXUE | — |
| 18272536 | Systems and Methods for Base Editing Of HBG1/2 Gene Promoter and Fetal Hemoglobin Induction | LEITH, NANCY J | — |
| 17801907 | RECOMBINANT FIBCD1 AND USE THEROF IN THE TREATMENT OF MUSCLE ATROPHY | WHITE, ASHLEY TAYLOR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | LANDSMAN, ROBERT S | 24d overdue |
| 18541691 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | VALENROD, YEVGENY | 11d overdue |
| 18042015 | COMPOSITIONS AND METHOD FOR TREATING THALASSEMIA | WHITEMAN, BRIAN A | 2d overdue |
| 18041873 | Use of Amylase or Maltose to Treat or Prevent Neurodegeneration | O'NEILL, MARISOL ANN | 9d |
| 17258533 | USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS | GRABER, JAMES J | 79d |
| 18858952 | SMALL MOLECULE MODULATORS OF HUMAN PREGNANE X RECEPTOR | COUGHLIN, MATTHEW P | — |
| 18681966 | METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION | WANG, RUIXUE | — |
| 18565700 | INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER | MERTZ, PREMA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1672 | 2 |
| 1628 | 2 |
| 1636 | 2 |
| 1634 | 2 |
| 1653 | 2 |
| 1626 | 1 |
| 1647 | 1 |
| 1633 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858952 | SMALL MOLECULE MODULATORS OF HUMAN PREGNANE X RECEPTOR | COUGHLIN, MATTHEW P | 1626 | §102§103§112DP | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18681966 | METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION | WANG, RUIXUE | 1672 | §102§103§112 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18541691 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | VALENROD, YEVGENY | 1628 | §112 | Final Rejection | 11d overdue | Pending | Dec 15, 2023 |
| 18565700 | INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER | MERTZ, PREMA MARIA | — | §103§112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18564987 | METHODS AND COMPOSITIONS FOR TRANSDUCTION OF NK CELLS | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | — | Pending | Nov 28, 2023 |
| 18272536 | Systems and Methods for Base Editing Of HBG1/2 Gene Promoter and Fetal Hemoglobin Induction | LEITH, NANCY J | 1636 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18257680 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | CORNET, JEAN P | 1628 | §103§112DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | LANDSMAN, ROBERT S | 1647 | §103 | Final Rejection | 24d overdue | Pending | Mar 14, 2023 |
| 18042015 | COMPOSITIONS AND METHOD FOR TREATING THALASSEMIA | WHITEMAN, BRIAN A | 1636 | §103 | Final Rejection | 2d overdue | Pending | Feb 17, 2023 |
| 18041873 | Use of Amylase or Maltose to Treat or Prevent Neurodegeneration | O'NEILL, MARISOL ANN | 1633 | §102§103 | Non-Final OA | 9d | Pending | Feb 16, 2023 |
| 18003093 | METHODS OF GENERATING AN ACTIVATION INDUCIBLE EXPRESSION SYSTEM IN IMMUNE CELLS | LEONARD, ARTHUR S | 1631 | §103 | Final Rejection | — | Pending | Dec 22, 2022 |
| 17917198 | B7-H3 CHIMERIC ANTIGEN RECEPTORS | RIGA, MICHAEL ANGELO | 1634 | §102§103 | Final Rejection | 72d overdue | Pending | Oct 05, 2022 |
| 17801907 | RECOMBINANT FIBCD1 AND USE THEROF IN THE TREATMENT OF MUSCLE ATROPHY | WHITE, ASHLEY TAYLOR | 1653 | §103§112 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17783040 | Method for Preparing CD7-Negative, CD3-Positive T Cells | GRABER, JAMES J | 1631 | §103Other | Non-Final OA | — | Pending | Jun 07, 2022 |
| 17605639 | GENE KNOCK-OUTS TO IMPROVE T CELL FUNCTION | ABBOTT, KODYE LEE | 1634 | §102§103§112Other | Final Rejection | — | Pending | Oct 22, 2021 |
| 16467358 | DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY | MOSS, NATALIE M | 1653 | §101§103 | Non-Final OA | 70d | Pending | Jun 06, 2019 |
| 17819810 | TUMOR SUPPRESSION BY MODULATION OF NON-CANONICAL AUTOPHAGY (LAP) IN MYELOID CELLS | GAO, ASHLEY HARTMAN | 1678 | §103§112 | Final Rejection | — | Pending | Aug 15, 2022 |
| 17258533 | USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS | GRABER, JAMES J | 1631 | §103Other | Final Rejection | 79d | Pending | Jan 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSt. Jude Children's Research Hospital Inc. has 18 pending office actions as of October 2026, spread across 10 art units and 16 examiners.
Ruixue Wang has the most, with 2 of St. Jude Children's Research Hospital Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
